Arkolith/Insider Trading/XENE/Form 4

Mortimer Ian

PRESIDENT & CEO, DirectorXenon Pharmaceuticals Inc. (XENE) · full profile →Form 4 · filed Jan 2, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.8M
Net Open-Market Flow
-$1.8M
Transactions
4
3 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 2, 2026Sell(S)38K$44.40$1.7M8K
Jan 2, 2026Option exercise(M)40K$7.49$300K46K
Jan 2, 2026Sell(S)2K$44.93$93K6K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 2, 2026Option exercise(M)40K—$00

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-001172) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML